Invesco
MBX

Invesco’s MBX Biosciences MBX Stock Holding History

Invesco’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$822K Buy
27,525
+6,322
+30% +$215K ﹤0.01% 2954
2025
Q4 		$669K Buy
21,203
+9,415
+80% +$228K ﹤0.01% 3084
2025
Q3 		$206K Buy
+11,788
New +$158K ﹤0.01% 3558

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Invesco's MBX Position: Q1 2026 in Review

Invesco increased its MBX Biosciences (MBX) stake by 30% in Q1 2026, buying an estimated $215K and bringing the position to 27,525 shares worth $822K. The position accounts for ﹤0.01% of the portfolio, ranked #2954.

Invesco first reported a position in MBX in Q3 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Invesco held 27,525 shares of MBX Biosciences worth $822K as of Q1 2026.
  • Invesco bought 6,322 MBX Biosciences shares in Q1 2026, an estimated $215K.
  • MBX Biosciences made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2954 holding.
  • Invesco first reported a position in MBX Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.